How Many Diseases Are Colorectal Cancer?
The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differ...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2012/564741 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545388968542208 |
|---|---|
| author | A. Greystoke S. A. Mullamitha |
| author_facet | A. Greystoke S. A. Mullamitha |
| author_sort | A. Greystoke |
| collection | DOAJ |
| description | The development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of “colorectal cancer.” |
| format | Article |
| id | doaj-art-a198247feae34312b547e758fd6884db |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-a198247feae34312b547e758fd6884db2025-02-03T07:25:59ZengWileyGastroenterology Research and Practice1687-61211687-630X2012-01-01201210.1155/2012/564741564741How Many Diseases Are Colorectal Cancer?A. Greystoke0S. A. Mullamitha1Department of Medical Oncology, Christie NHS Foundation Trust, Manchester M20 4BX, UKDepartment of Medical Oncology, Christie NHS Foundation Trust, Manchester M20 4BX, UKThe development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of “colorectal cancer.”http://dx.doi.org/10.1155/2012/564741 |
| spellingShingle | A. Greystoke S. A. Mullamitha How Many Diseases Are Colorectal Cancer? Gastroenterology Research and Practice |
| title | How Many Diseases Are Colorectal Cancer? |
| title_full | How Many Diseases Are Colorectal Cancer? |
| title_fullStr | How Many Diseases Are Colorectal Cancer? |
| title_full_unstemmed | How Many Diseases Are Colorectal Cancer? |
| title_short | How Many Diseases Are Colorectal Cancer? |
| title_sort | how many diseases are colorectal cancer |
| url | http://dx.doi.org/10.1155/2012/564741 |
| work_keys_str_mv | AT agreystoke howmanydiseasesarecolorectalcancer AT samullamitha howmanydiseasesarecolorectalcancer |